07 November 2018 - Events
Bioven – an immuno-oncology business with a lead product in phase III trials and a pipeline of pre-clinical assets.
Mologic Limited – a point-of-care diagnostics spin-out from Alere.
Grampian BioPartners – a specialist life science business angel syndicate, able to act as a micro-lead on specialist life-science deals.
Writer to Her Majesty’s Signet
A Q & A with James Shaw, Biotech and Money, Drugs & Dealers, May 2016
What You Need To Know About Intellectual Property And Brexit, Financier Worldwide, January 2017
A New Cambrian Era For Biotech Startups, Drugs & Dealers, January 2018
JAG Shaw Baker Thought leadership content
Innovative Financing Instruments, A Better Alternative? 1/23/17
The New World Order Of Innovative Financings, 11/9/16
The Top Four Tips You Need To Prep For A Biotech IPO, 9/12/16
The Effect Of Brexit On Venture Funding, 7/11/2016
In The News: James Shaw Talks To Drugs & Dealers Magazine, 5/13/16
Crossing The Valley Of Death: Funding, Financing And Strategy At Biotech & Money London, 2/3/2016
Mention, A Rare Launch in Europe: A Big New Law Firm Dedicated To Tech Startups, Techcrunch, 9/24/2013
Society of Scottish Lawyers in London, committee member
Early Stage Funding, Startup and SME club, 3/8/2018
Funding AI, VR And AR Startups In MedTech For Growth, February 2018 (panel member)
What Does The Future Hold For Digital Health? Biotechs and the City, September 2017 (panel member)
Fintech Phenomena; Cross Border Growth & Success, Digital Freedom Festival, Riga, 2017
Crossing The Valley Of Death: Funding, Financing & Strategy, Biotech & Money 2016 (panel member)
Me in a minute
I'm passionate about helping entrepreneurs and investors create a new era in healthcare
We’ve all seen the headlines and heard the lawyer jokes. Surveys say that half of all lawyers wouldn’t enter the profession if they had it to do over or even recommend being a lawyer to their children, so why did I become a lawyer? The reason is simple; I can make a difference. Whether it’s helping life sciences and biotech spinouts become companies that can develop novel therapies or working with startups to help them bring new technologies like virtual reality, augmented reality and artificial intelligence, to market, I get to help these entrepreneurs and investors, create a new era in healthcare.
From genetic research and emergency room management to clinical trials, virtual nurses and drug discovery, these new technologies are already changing how we interact with healthcare globally; and as a lawyer in this sector, I get to be a part and work alongside an industry that has the potential to redesign how health care is done and how consumers access and use it.
Now, do you want to hear a lawyer joke?
InsightView all Firm insight
17 October 2018 - In The Press